CAR-T cells: from cancer to autoimmunity
October 12, 2022
Professor Dimitrios Mougiakakos
Professor Dimitrios Mougiakakos is the director of the Hematology and Oncology department at the Otto-von-Guericke University in Magdeburg, Germany. In this episode, he joins us to discuss the exciting potential for CAR T cell therapy for autoimmune disease and how his team has approached GMP manufacturing in the clinical setting. He explains the challenges faced in setting up cell therapy for systemic lupus erythematosus (SLE), and the future of cell and gene therapy in different indications.
How did you first become interested in cell and gene therapy?
What led to your recent work treating lupus?
What is the benefit of using CAR T cell therapy to target B cells in lupus?
What have been the results of the human trials so far?
What were the operational challenges of setting up cell therapy in your clinical setting?
How did advance in technologies help you overcome those challenges?
Do we need decentralized CAR T cell production in the academic setting?
What challenges remain? Where could technology make an impact?
Where is the brightest future for cell and gene therapies?